drugset / Trial / NCT06685081
Dexmedetomidine for Improved Pain Relief and Recovery in Spine Surgery
RandomizedParallel-groupDouble-blindTreatment
Summary
Chronic low back pain (CLBP) is a prevalent condition causing significant pain, disability, and reduced quality of life. While various treatments like exercise, NSAIDs, and spinal manipulation are recommended, their effectiveness is limited. Epidural steroid injections can provide short-term relief but may not be cost-effective and have associated risks. Dexmedetomidine (DXM) is a selective α2-adrenergic agonist with analgesic properties. It has been used as an adjuvant to anesthetics and analgesics to enhance pain relief and reduce opioid consumption. Using DXM in conjunction with local anesthetics for regional blocks has shown promising results in improving analgesia and functional outcomes.
Timeline
- Start
- 2024-07-01
- Primary completion
- 2024-10-15
- Completion
- 2024-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dexmedetomidine | Other / unclassified | 0.25 ug/kg | — |
| Comparator | Dexmedetomidine | Other / unclassified | 0.5 ug/kg | — |
| Comparator | Dexmedetomidine | Other / unclassified | 0.75 ug/kg | — |
| Comparator | Dexmedetomidine | Other / unclassified | 1 ug/kg | — |
| Comparator | Lidocaine | Other / unclassified | 1.5 % | Other |
| Comparator | Lidocaine | Other / unclassified | 2 ml | Other |
| Comparator | Triamcinolone | Other / unclassified | 2 ml | Other |
Indications
No indication recorded.